Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Publication
, Journal Article
Eckhardt, CM; Cummings, MJ; Rajagopalan, KN; Borden, S; Bitan, ZC; Wolf, A; Kantor, A; Briese, T; Meyer, BJ; Jacobson, SD; Scotto, D; Shaz, B ...
Published in: Trials
November 17, 2020
An amendment to this paper has been published and can be accessed via the original article.
Duke Scholars
Published In
Trials
DOI
EISSN
1745-6215
Publication Date
November 17, 2020
Volume
21
Issue
1
Start / End Page
927
Location
England
Related Subject Headings
- General & Internal Medicine
- Cardiovascular System & Hematology
- 4203 Health services and systems
- 4202 Epidemiology
- 3202 Clinical sciences
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Eckhardt, C. M., Cummings, M. J., Rajagopalan, K. N., Borden, S., Bitan, Z. C., Wolf, A., … O’Donnell, M. R. (2020). Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), 927. https://doi.org/10.1186/s13063-020-04877-z
Eckhardt, Christina M., Matthew J. Cummings, Kartik N. Rajagopalan, Sarah Borden, Zachary C. Bitan, Allison Wolf, Alex Kantor, et al. “Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.” Trials 21, no. 1 (November 17, 2020): 927. https://doi.org/10.1186/s13063-020-04877-z.
Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, et al. Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Nov 17;21(1):927.
Eckhardt, Christina M., et al. “Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.” Trials, vol. 21, no. 1, Nov. 2020, p. 927. Pubmed, doi:10.1186/s13063-020-04877-z.
Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, Kantor A, Briese T, Meyer BJ, Jacobson SD, Scotto D, Mishra N, Philip NM, Stotler BA, Schwartz J, Shaz B, Spitalnik SL, Eisenberger A, Hod Jessica Justman EA, Cheung K, Lipkin WI, O’Donnell MR. Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Nov 17;21(1):927.
Published In
Trials
DOI
EISSN
1745-6215
Publication Date
November 17, 2020
Volume
21
Issue
1
Start / End Page
927
Location
England
Related Subject Headings
- General & Internal Medicine
- Cardiovascular System & Hematology
- 4203 Health services and systems
- 4202 Epidemiology
- 3202 Clinical sciences
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology